Mainz Biomed Continues Its Noble Mission Of Saving Lives With Early Cancer Detection

While Pfizer Inc PFE announced layoffs due to slumping sales of the COVID-19 vaccine that made it cut its full-revenue forecast earlier this month, a molecular genetics diagnostic company that specializes in the early detection of cancer, Mainz Biomed N.V. MYNZ announced it got a new executive on board as it continues to commercialize its flagship product across the globe.

Tarrin Khairi-Taraki is Mainz Biomed’s EMEA Vice President of Commercial Operations. With his highly-impressive track record and abundant experience in the medical diagnostic field, the former Natera Manager will be overseeing Mainz Biomed’s sales and support in EMEA with the aim of ensuring a successful commercialization of ColoAlert® colorectal cancer test across the region.

While occupying the post of Co-Founder and VP of Business Development at Eluthia, Tarrin played an important role in establishing the company as one of the leading laboratories offering prenatal testing solutions to healthcare facilities in Germany and Austria. Tarrin also served as the Regional Manager for DACH and BENELUX at Natera that is renowned for its non-invasive, cell-free DNA testing technology that made it one of the four global leaders in prenatal screening. His market analysis and business development strategies propelled Natera's innovative Panorama Test to expand its presence across the DACH region, as well as in Austria and the Netherlands.

Pfizer Embarks On A Cost-Savings Journey

With about 83,000 employees worldwide, Pfizer announced it will be slashing its headcount in face of fading demand for its COVID-19 vaccine. What a difference a year makes as last year, Pfizer made record revenue that topped $100 billion. The Covid-19 vaccine that Pfizer developed with BioNTech SE BNTX along with antiviral treatment Paxlovid brought in more than $56 billion. But, with this unprecedented virus no longer holding the world hostage, Pfizer is now facing a reality of weaker-than-expected sales. Earlier this month, it announced that throughout next year, it aims to save $3.5 billion by lowering its expenses, including layoffs, but it did not reveal more details of its cost-saving strategy.

Pfizer Is Officially On Another Race Against Moderna And Novavax

Today, October 26th, Pfizer and BioNTech revealed positive results from their early trial of a combined Covid-19 and influenza vaccine. When compared with two stand-alone vaccines, Pfizer and BioNTech reported that their shot performed well. The synergy that Pfizer and BioNTech created promises to simplify immunization practices while lessening the impact of the two respiratory diseases.

 Moderna Inc MRNA and Novavax Inc NVAX are also developing their own combination vaccines. Earlier this month, Moderna announced its combination vaccine could be ready in 2025. As for Novavax, who revealed back in May its plans to also trim its workforce by 25% due to a steeper than expected revenue drop, it also reported encouraging results. Novavax revealed encouraging results from its Phase 2 trial data that showed its shot was tolerated well, with a reassuring preliminary safety profile and robust preliminary immune response.

Saving Lives, One Step At A Time 

The difference is that Pfizer and Moderna made a big wager on Covid-19 while Mainz Biomed is bravely going against diseases that the world has been failing to cure throughout its modern history. Unlike viruses that are foreign invaders, cancer is born out of own cells. Dr Ruediger Dahlke even made a comparison saying how this sneaky disease is in fact a caricature of modern society and its endless pursuit of economic growth that is destroying the planet in terms of carbon emissions, deforestation, etc. Throughout our history, Dahlke argues that every era came with its unique set of diseases, as a natural mechanism to correct human wrongdoings. Dr. Dahlke’s observation certainly makes one to think, especially as every cancer is caused by a different set of mutations and with myriads of mutations, a drug that works for one patient, might not at all have an effect on another. This is why early prevention is our best shot, at the moment, at least until we figure out what we are doing wrong to provide science with that missing piece of the puzzle. Mainz Biomed beautifully responded to this urging need by addressing the third most common cancer globally while it also continues to develop PancAlert, a novel screening test for pancreatic cancer.

DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.